This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EQRX EQRx (EQRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About EQRx Stock (NASDAQ:EQRX) 30 days 90 days 365 days Advanced Chart Get EQRx alerts:Sign Up Key Stats Today's Range$2.34▼$2.3450-Day Range$2.04▼$2.4752-Week Range$1.58▼$5.55VolumeN/AAverage Volume3.30 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.Read More… Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address EQRX Stock News HeadlinesPGA Championship 2025: Super group of Scottie Scheffler, Rory McIlroy and Xander Schauffele all eject on SAME holeMay 17, 2025 | msn.comHepatitis A outbreak declared in Los Angeles County: Here's what we knowMay 9, 2025 | msn.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.June 1, 2025 | Altimetry (Ad)Sam Altman urges lawmakers against regulations that could ‘slow down’ U.S. in AI race against ChinaMay 9, 2025 | msn.comGuggenheim Securities Hires Jami Rubin to Expand Healthcare Investment Banking PracticeJanuary 10, 2025 | finance.yahoo.comAUROW Aurora Innovation, Inc. WT EXP 110326November 13, 2024 | seekingalpha.com89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesNovember 7, 2024 | markets.businessinsider.comBreast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightOctober 2, 2024 | finance.yahoo.comSee More Headlines EQRX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of EQRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that EQRx investors own include Meta Platforms (META), NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Exxon Mobil (XOM), CrowdStrike (CRWD) and GE Aerospace (GE). Company Calendar Today5/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EQRX CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees362Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$169.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.33% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio22.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.98Miscellaneous Outstanding Shares487,420,000Free Float398,218,000Market Cap$1.14 billion OptionableOptionable Beta0.48 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EQRX) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EQRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.